Home / Companies / News / Covid-19 fight: Indian companies join race to develop blood products

Covid-19 fight: Indian companies join race to develop blood products

As the development of vaccines or any drug will take time, research on Sars-CoV-2 neutralising antibodies is gaining ground to fill an unmet demand in therapy

Premium

Ahmedabad-based Intas Pharma’s Plasma Division and Mumbai-headquartered Bharat Serums and Vaccines (BSVL) are looking to produce what are commonly known as hyperimmune globlulins

Sohini Das Mumbai

5 min read Last Updated : Sep 26 2020 | 6:06 AM IST

Covid-19 has already claimed about a million lives globally and the toll is rising. As the development of vaccines or any drug will take time, research on Sars-CoV-2 neutralising antibodies is gaining ground to fill an unmet demand in therapy.

Global majors like Roche and Takeda are working on antibody therapies, and Indian firms aren’t far behind. Ahmedabad-based Intas Pharma’s Plasma Division and Mumbai-headquartered Bharat Serums and Vaccines (BSVL) are looking to produce what are commonly known as hyperimmune globlulins from convalescent plasma from recovered patients and horses.

What are hyperimmune globulins?

A patient who has recovered from Covid-19 has

Topics : Coronavirus Coronavirus Tests Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in